R-7128

• CAT Number: I005591
• CAS Number: 940908-79-2
• Molecular Formula: C18H26FN3O6
• Molecular Weight: 399.41
• Purity: ≥95%
• Target: HCV
• Solubility: 10 mM in DMSO
• Storage: Store at -20°C
• IUPAC Name: [(2R,3R,4R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-4-fluoro-4-methyl-3-(2-methylpropanoyloxy)oxolan-2-yl]methyl 2-methylpropanoate
• InChI: InChI=1S/C18H26FN3O6/c1-9(2)14(23)26-8-11-13(28-15(24)10(3)4)18(5,19)16(27-11)22-7-6-12(20)21-17(22)25/h6-7,9-11,13,16H,8H2,1-5H3,(H2,20,21,25)/t11-,13-,16-,18-/m1/s1
• InChIKey: MLESJYFEMSJZLZ-MAAOGQSESA-N
• SMILES: CC(C)C(=O)OCC1C(C(C(O1)N2C=CC(=NC2=O)N)(C)F)OC(=O)C(C)C

R-7128（Cat No.:I005591）, also known as Mericitabine, is a selective nucleoside analog inhibitor that targets the RNA-dependent RNA polymerase (NS5B) of the hepatitis C virus (HCV). It exhibits activity against all genotypes of HCV, making it a broad-spectrum antiviral agent. By inhibiting NS5B, R-7128 disrupts viral replication and reduces HCV viral load. This compound shows potential as a therapeutic option for the treatment of hepatitis C, offering a targeted approach to combatting the virus across different HCV genotypes.

Reference

[1]. R-7128: RNA-directed RNA polymerase (NS5B) inhibitor treatment of hepatitis C virus infection By Cole, P.; Castaner, R.; Bolos, J.From Drugs of the Future (2009), 34(4), 282-290. 


[2]. Godzik P, Komorowski M, Cielecka-Kuszyk J, Madaliński K. Inhibitors of hepatitis C virus–current standards and status of investigationsPrzegl Epidemiol. 2010;64(4):473-8.